GSK Strikes Up To $750 Million Deal For Cancer-Targeting Drug - MS
READ HERE
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
GSK strikes up to $750 million deal for cancer-targeting drug
GSK LSE:GSK said on Tuesday it had agreed to a deal worth up to $750 million to buy a trispecific T cell-engager, a drug designed to help T-cells target cancer, from private biotechnology firm Chimagen Biosciences.